Stocks and Investing
Stocks and Investing
Fri, September 13, 2024
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Gregory Renza Maintained (VRDN) at Buy with Increased Target to $44 on, Sep 13th, 2024
Gregory Renza of RBC Capital, Maintained "Viridian Therapeutics, Inc." (VRDN) at Buy with Increased Target from $35 to $44 on, Sep 13th, 2024.
Gregory has made no other calls on VRDN in the last 4 months.
There are 7 other peers that have a rating on VRDN. Out of the 7 peers that are also analyzing VRDN, 0 agree with Gregory's Rating of Hold.
These are the ratings of the 7 analyists that currently disagree with Gregory
- Richard Law of "Goldman Sachs" Maintained at Strong Buy with Increased Target to $31 on, Thursday, September 12th, 2024
- Serge Belanger of "Needham" Maintained at Strong Buy with Increased Target to $38 on, Wednesday, September 11th, 2024
- Douglas Tsao of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $27 on, Tuesday, September 10th, 2024
- Julian Harrison of "BTIG" Maintained at Strong Buy with Increased Target to $56 on, Tuesday, September 10th, 2024
- Leland Gershell of "Oppenheimer" Reiterated at Buy with Decreased Target to $28 on, Monday, August 12th, 2024
- Laura Chico of "Wedbush" Reiterated at Buy and Held Target at $42 on, Monday, July 29th, 2024
- Andy Chen of "Wolfe Research" Initiated at Buy on, Tuesday, June 11th, 2024
Contributing Sources